查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088756

肝病診斷市場：按交付方式、疾病類型和最終用戶分類的全球市場預測 – 2026-2032 年

Liver Disease Diagnostics Market by Offering, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肝病診斷市場將成長至 275.7 億美元，複合年成長率為 9.51%。

主要市場統計數據
基準年 2025 146億美元
預計年份：2026年 158.9億美元
預測年份 2032 275.7億美元
複合年成長率 (%) 9.51%

肝病診斷市場概覽

肝病的診斷正在從回顧性確認晚期疾病轉變為基於風險的早期檢測，檢測範圍涵蓋基層醫療、肝病學、感染疾病、腫瘤學和移植學等領域。

肝病診斷的變革性變化

肝病診斷模式正受到三個結構性變化的影響：代謝性肝病負擔日益加重、公共衛生領域更加重視根除病毒性肝炎，以及需要減少可預防的末期肝硬化的檢測。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改善影像解讀、風險預測、工作流程優先排序和時間序列監測，為肝臟疾病的整體診斷增添了價值。目前正在評估各種 AI 工具在提高超音波影像品質、表徵肝臟病變、CT 和 MRI 分割、量化脂肪變性以及評估纖維化程度方面的應用。

關鍵區域洞察

亞太地區（包括中國、印度、日本、韓國和澳洲）人口大規模，乙型肝炎負擔持續沉重，代謝性肝病病例迅速增加，且診斷基礎設施不斷完善，因此被列為重點關注區域。世界衛生組織已將西太平洋和東南亞地區列為全球病毒性肝炎負擔的主要貢獻者，並強調需要大規模進行乙型和丙型肝炎檢測、肝功能評估、纖維化分層和肝細胞癌監測。在北美，先進的保險報銷體系、強大的影像技術以及非侵入性纖維化檢測的廣泛應用正在推動臨床需求，尤其是在肥胖、糖尿病、酒精性肝病和多器官相關肝病（MASLD）病例不斷增加的情況下。

主要區域洞察

東南亞國協的需求主要受以下因素驅動：大規模的篩檢族群、多個成員國乙型肝炎的高發生率，以及不斷擴張的私立醫院網路提高了肝酵素檢測、肝炎血清學檢查、超音波和纖維化評估的可及性。海灣合作理事會（GCC）國家正在投資數位醫療、專科護理和預防性篩檢，而糖尿病和肥胖症的高發生率則推動了對代謝相關肝病（MASLD）診斷、非侵入性纖維化評估和綜合轉診途徑的需求。

主要國家的概況

由於分子檢測、彈性成像、磁振造影以及專業肝病網路的廣泛應用，美國在進行進行性肝病診斷領域處於領先地位。而加拿大則更著重於透過其公共醫療體系進行以指引為基礎的肝炎和纖維化評估。墨西哥和巴西由於代謝性疾病的增加以及為改善基層基層醫療和實驗室服務的可及性而加強，迫切需要擴充性的肝炎檢測、肝酵素篩檢和非侵入性纖維化評估工具。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床驗證的非侵入性診斷流程，這些流程應整合肝功能檢查、肝炎檢測、纖維化評分、彈性成像和影像檢查結果，從而為具體的治療決策提供依據。最有效的解決方案應能縮短檢驗時間，及早發現進行性纖維化，並無縫融入基層醫療和專科醫師的工作流程。

調查方法

本執行摘要基於符合既定市場研究實務的系統性二手研究途徑。所考慮的資訊來源包括公共衛生資料集、同行評審的肝病學文獻、臨床指南出版刊物、法律規範、技術採納的實證數據以及臨床實驗室、診斷成像、分子檢測和數位健康領域的已記錄趨勢。

結論

由於醫療系統面臨病毒性肝炎、惡性急性肝病、酒精性肝病、肝硬化和肝癌等多種疾病的複雜負擔，肝病診斷市場正進入一個影響深遠的時期。早期檢測、綜合檢測方案和非侵入性纖維化評估在改善治療效果和降低後續治療成本方面發揮著至關重要的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肝病診斷市場：依產品/服務分類

  • 切片檢查技術
    • 腹腔鏡肝臟切片檢查
    • 經皮肝穿刺切片檢查
    • 經靜脈肝切片檢查
  • 驗血
    • 丙氨酸轉氨酶試驗
    • 天門冬胺酸轉氨酶試驗
    • γ-谷氨醯轉肽酶試驗
  • 內視鏡檢查
  • 診斷影像
    • 電腦斷層掃描
    • MRI
    • 超音波

第8章 肝病診斷市場：依疾病類型分類

  • 急性肝炎
  • 酒精性肝臟疾病
  • 慢性肝炎
  • 肝硬化
  • 肝細胞癌
  • 非酒精性脂肪肝疾病

第9章 肝病診斷市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第10章 肝病診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第11章 肝病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章 肝病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第14章：公司簡介

  • Abbott Laboratories
  • Amgen Inc.
  • Argon Medical Devices, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Boston Scientific Corporation
  • Cook Medical Incorporated
  • Echosens by Astor Partners Srl
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hepatiq, Inc.
  • Hologic, Inc.
  • Horiba, Ltd.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Medtronic PLC
  • Merck & Co., Inc.
  • Perspectum Ltd.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Ri.Mos. Srl
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-B9334AD6C587

The Liver Disease Diagnostics Market is projected to grow by USD 27.57 billion at a CAGR of 9.51% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.60 billion
Estimated Year [2026] USD 15.89 billion
Forecast Year [2032] USD 27.57 billion
CAGR (%) 9.51%

Liver Disease Diagnostics Market Introduction

Liver disease diagnostics are moving from reactive confirmation of advanced disease toward earlier, risk-based detection across primary care, hepatology, infectious disease, oncology, and transplant pathways.

The clinical need is substantial. The World Health Organization reported that viral hepatitis caused about 1.3 million deaths in 2022, while hepatitis B and C affected an estimated 304 million people worldwide. In parallel, metabolic dysfunction-associated steatotic liver disease, formerly NAFLD, is estimated in peer-reviewed global analyses to affect roughly one in three adults. These trends are increasing demand for liver function tests, hepatitis serology, molecular diagnostics, fibrosis biomarker panels, elastography, ultrasound, CT, MRI, and point-of-care testing.

For market participants, the opportunity is strongest where diagnostics improve early case finding, stratify fibrosis risk, guide antiviral or metabolic therapy, and support surveillance for cirrhosis and hepatocellular carcinoma.

Transformative Shifts in Liver Disease Diagnostics

The liver disease diagnostics landscape is being reshaped by three structural shifts: the rising burden of metabolic liver disease, renewed public health focus on viral hepatitis elimination, and the need to reduce avoidable late-stage cirrhosis detection.

Clinical pathways are shifting from single-test evaluation to integrated diagnostic algorithms. Routine liver enzyme testing is increasingly paired with platelet count-based scores such as FIB-4, enhanced liver fibrosis panels, transient elastography, magnetic resonance elastography, and targeted molecular assays. This combination supports non-invasive fibrosis staging and reduces dependence on liver biopsy, which remains valuable but is limited by sampling error, cost, and procedural risk.

Healthcare systems are also prioritizing decentralization. Community-based hepatitis testing, reflex laboratory workflows, home specimen collection, and digital referral pathways are improving access while shortening the time between abnormal screening results and specialist management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding value across liver disease diagnostics by improving image interpretation, risk prediction, workflow triage, and longitudinal monitoring. AI-enabled tools are being evaluated for ultrasound quality enhancement, liver lesion characterization, CT and MRI segmentation, steatosis quantification, and fibrosis estimation.

The cumulative impact is operational as well as clinical. Algorithms can help prioritize patients with abnormal liver function tests, combine laboratory and electronic health record data to flag elevated fibrosis risk, and reduce reporting variability in imaging-heavy pathways. In hepatocellular carcinoma surveillance, AI has potential to support earlier detection when curative options are more feasible.

Adoption must remain evidence-led. Industry leaders should validate AI across diverse populations, document performance by disease etiology and ethnicity, monitor bias, and align with medical device software regulations, data privacy rules, and clinician-in-the-loop governance.

Key Regional Insights

Asia-Pacific is a high-priority region because it combines large populations, persistent hepatitis B burden, rapidly rising metabolic liver disease, and expanding diagnostic infrastructure in China, India, Japan, South Korea, and Australia. The WHO has identified the Western Pacific and South-East Asia as major contributors to the global viral hepatitis burden, reinforcing the need for scalable hepatitis B and C testing, liver function assessment, fibrosis stratification, and hepatocellular carcinoma surveillance. North America benefits from advanced reimbursement frameworks, strong imaging capacity, and growing adoption of non-invasive fibrosis testing, especially as obesity, diabetes, alcohol-related liver disease, and MASLD increase clinical demand.

Latin America shows increasing need for affordable hepatitis testing, liver enzyme screening, and fibrosis risk stratification, with Brazil and Mexico serving as key access hubs as health systems expand prevention and chronic disease management. Europe is shaped by structured public health programs, EU regulatory oversight, and strong uptake of elastography, biomarker-led pathways, and guideline-based hepatitis elimination initiatives.

The Middle East faces rising metabolic risk linked to diabetes and obesity, supporting demand for early liver disease diagnostics, non-invasive fibrosis assessment, and surveillance pathways for high-risk patients. Africa remains underserved despite meaningful viral hepatitis burden, making scalable serology, point-of-care testing, confirmatory molecular diagnostics, laboratory quality systems, and referral infrastructure essential to improve detection and continuity of care.

Key Group Insights

ASEAN demand is supported by large screening-eligible populations, hepatitis B prevalence in several member states, and expanding private hospital networks that are increasing access to liver enzyme testing, hepatitis serology, ultrasound, and fibrosis assessment. The GCC is investing in digital health, specialty care, and preventive screening, while high diabetes and obesity prevalence increase demand for MASLD diagnostics, non-invasive fibrosis assessment, and integrated referral pathways.

The European Union is a leader in standardized regulatory pathways, in vitro diagnostic oversight, and public health-led hepatitis elimination strategies, supporting adoption of validated laboratory assays, elastography, and evidence-based clinical algorithms. BRICS countries represent volume-driven opportunity due to large patient pools, domestic diagnostic manufacturing, and expanding insurance coverage, though access levels vary widely across urban and rural settings.

G7 markets lead in advanced imaging, molecular diagnostics, AI validation, laboratory automation, and clinical guideline adoption, strengthening uptake of integrated diagnostic pathways for hepatitis, MASLD, cirrhosis, and liver cancer surveillance. NATO countries overlap with many high-income health systems where resilient supply chains, data security, interoperable diagnostic networks, and continuity of essential testing are strategic priorities for liver disease diagnostics.

Key Country Insights

The United States leads in advanced liver disease diagnostics through broad availability of molecular testing, elastography, MRI, and specialty hepatology networks, while Canada emphasizes guideline-based hepatitis and fibrosis assessment through public healthcare systems. Mexico and Brazil show strong need for scalable hepatitis testing, liver enzyme screening, and non-invasive fibrosis tools as metabolic disease increases and access initiatives expand across primary care and reference laboratories.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support adoption through structured care pathways, public health screening programs, advanced imaging capacity, and growing use of non-invasive fibrosis assessment, while Russia presents demand linked to viral hepatitis, alcohol-related liver disease, and uneven regional access to specialist diagnostics. China and India represent major volume opportunities due to large populations and combined viral and metabolic liver disease burden, with expanding diagnostic infrastructure supporting hepatitis testing, liver function panels, ultrasound, molecular assays, and fibrosis risk stratification.

Japan, Australia, and South Korea offer sophisticated diagnostic ecosystems with strong imaging capacity, aging populations, robust laboratory networks, and high readiness for AI-assisted workflows, laboratory automation, and hepatocellular carcinoma surveillance. These countries also benefit from guideline-oriented clinical practice and established specialty care systems that support early identification of fibrosis, cirrhosis, and liver cancer risk.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated, non-invasive diagnostic pathways that connect liver function tests, hepatitis assays, fibrosis scores, elastography, and imaging into actionable care decisions. The strongest solutions will shorten time to diagnosis, identify advanced fibrosis earlier, and integrate seamlessly into primary care and specialist workflows.

Organizations should build evidence packages that demonstrate sensitivity, specificity, cost-effectiveness, workflow impact, and improved referral quality. Partnerships with laboratories, radiology networks, digital health vendors, payers, and public health agencies can expand access and improve test adherence.

Strategic investment should focus on affordable point-of-care testing, multiplex molecular platforms, AI-enabled imaging, companion diagnostics for emerging liver therapies, and interoperable data systems that support longitudinal monitoring and population health management.

Research Methodology

This executive summary is based on a structured secondary research approach aligned with established market intelligence practices. Sources considered include public health datasets, peer-reviewed hepatology literature, clinical guideline publications, regulatory frameworks, technology adoption evidence, and documented trends across laboratory diagnostics, imaging, molecular testing, and digital health.

The analysis emphasizes verified, data-backed indicators such as disease burden, diagnostic pathway evolution, technology readiness, regional healthcare infrastructure, and public health priorities. Qualitative synthesis was used to connect epidemiology, clinical practice, reimbursement dynamics, regulatory requirements, and innovation trends.

Insights were reviewed for relevance to liver disease diagnostics, including hepatitis testing, liver function testing, fibrosis assessment, MASLD evaluation, elastography, imaging, AI-enabled diagnostics, and hepatocellular carcinoma surveillance. No market sizing, market share, or forecasting assumptions were applied.

Conclusion

The liver disease diagnostics market is entering a high-impact phase as healthcare systems confront the combined burden of viral hepatitis, MASLD, alcohol-related liver disease, cirrhosis, and liver cancer. Early detection, integrated testing algorithms, and non-invasive fibrosis assessment are now central to improving outcomes and reducing downstream treatment costs.

Future market leadership will depend on diagnostic accuracy, affordability, evidence generation, digital integration, regulatory readiness, and equitable access. Organizations that connect laboratory, imaging, molecular, and AI-enabled insights into practical clinical pathways will be best positioned to support earlier intervention and measurable improvements in liver health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Liver Disease Diagnostics Market, by Offering

  • 7.1. Biopsy Techniques
    • 7.1.1. Laparoscopic Liver Biopsy
    • 7.1.2. Percutaneous Liver Biopsy
    • 7.1.3. Transvenous Liver Biopsy
  • 7.2. Blood-Based Tests
    • 7.2.1. Alanine Transaminase Test
    • 7.2.2. Aspartate Transaminase Test
    • 7.2.3. Gamma-Glutamyl Transpeptidase Test
  • 7.3. Endoscopy
  • 7.4. Imaging Diagnostics
    • 7.4.1. CT Scan
    • 7.4.2. MRI
    • 7.4.3. Ultrasound

8. Liver Disease Diagnostics Market, by Disease Type

  • 8.1. Acute Hepatitis
  • 8.2. Alcoholic Liver Disease
  • 8.3. Chronic Hepatitis
  • 8.4. Cirrhosis
  • 8.5. Hepatocellular Carcinoma
  • 8.6. Non-Alcoholic Fatty Liver Disease

9. Liver Disease Diagnostics Market, by End-User

  • 9.1. Diagnostic Laboratories
  • 9.2. Hospitals
  • 9.3. Research Institutes

10. Liver Disease Diagnostics Market, by Region

  • 10.1. Asia-Pacific
  • 10.2. North America
  • 10.3. Latin America
  • 10.4. Europe
  • 10.5. Middle East
  • 10.6. Africa

11. Liver Disease Diagnostics Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Liver Disease Diagnostics Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Concentration Analysis, 2025
    • 13.1.1. Concentration Ratio (CR)
    • 13.1.2. Herfindahl Hirschman Index (HHI)
  • 13.2. Recent Developments & Impact Analysis, 2025
  • 13.3. Product Portfolio Analysis, 2025
  • 13.4. Benchmarking Analysis, 2025

14. Company Profiles

  • 14.1. Abbott Laboratories
  • 14.2. Amgen Inc.
  • 14.3. Argon Medical Devices, Inc.
  • 14.4. Bayer AG
  • 14.5. Becton, Dickinson and Company
  • 14.6. Bio-Rad Laboratories, Inc.
  • 14.7. BioMerieux SA
  • 14.8. Boston Scientific Corporation
  • 14.9. Cook Medical Incorporated
  • 14.10. Echosens by Astor Partners S.r.l.
  • 14.11. Epigenomics AG
  • 14.12. F. Hoffmann-La Roche Ltd.
  • 14.13. Fujifilm Holdings Corporation
  • 14.14. Hepatiq, Inc.
  • 14.15. Hologic, Inc.
  • 14.16. Horiba, Ltd.
  • 14.17. Koninklijke Philips N.V.
  • 14.18. Laboratory Corporation of America Holdings
  • 14.19. Medtronic PLC
  • 14.20. Merck & Co., Inc.
  • 14.21. Perspectum Ltd.
  • 14.22. Qiagen N.V.
  • 14.23. Quest Diagnostics Incorporated
  • 14.24. Randox Laboratories Ltd.
  • 14.25. Ri.Mos. Srl
  • 14.26. Siemens Healthineers AG
  • 14.27. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LAPAROSCOPIC LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERCUTANEOUS LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSVENOUS LIVER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD-BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ALANINE TRANSAMINASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASPARTATE TRANSAMINASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GAMMA-GLUTAMYL TRANSPEPTIDASE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENDOSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENDOSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGING DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CT SCAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CT SCAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CT SCAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ULTRASOUND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ULTRASOUND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ULTRASOUND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ALCOHOLIC LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHRONIC HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CIRRHOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CIRRHOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CIRRHOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 124. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 125. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 126. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 127. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 146. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 148. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 152. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 153. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 154. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 184. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 195. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 196. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 203. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 204. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 209. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 210. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 211. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 212. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 217. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 218. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 223. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 224. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 225. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 237. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 238. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 239. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)